Any carboxylic ester where the carboxylic acid component is 2-furoic acid.
ChEBI ID: 50856
| Member | Definition | Role |
|---|---|---|
| 2-furancarboxylic acid [4-(6-amino-5-cyano-3-methyl-2,4-dihydropyrano[2,3-c]pyrazol-4-yl)phenyl] ester | 2-furancarboxylic acid [4-(6-amino-5-cyano-3-methyl-2,4-dihydropyrano[2,3-c]pyrazol-4-yl)phenyl] ester | |
| 2-furancarboxylic acid [4-(6-amino-5-cyano-3-propan-2-yl-2,4-dihydropyrano[2,3-c]pyrazol-4-yl)phenyl] ester | 2-furancarboxylic acid [4-(6-amino-5-cyano-3-propan-2-yl-2,4-dihydropyrano[2,3-c]pyrazol-4-yl)phenyl] ester | |
| fluticasone furoate | A trifluorinated corticosteroid that consists of 6alpha,9-difluoro-11beta,17alpha-dihydroxy-17beta-{[(fluoromethyl)sulfanyl]carbonyl}-16-methyl-3-oxoandrosta-1,4-diene bearing a 2-furoyl substituent at position 17. Used in combination with vilanterol trifenate for treatment of bronchospasm associated with chronic obstructive pulmonary disease. | fluticasone furoate |
| mometasone furoate | mometasone furoate |
| Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
|---|---|---|
| pre-1990 | 5 (0.49) | 18.7374 |
| 1990's | 64 (6.26) | 18.2507 |
| 2000's | 276 (26.98) | 29.6817 |
| 2010's | 510 (49.85) | 24.3611 |
| 2020's | 168 (16.42) | 2.80 |
| Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
|---|---|---|
| Trials | 489 (41.62%) | 5.53% |
| Reviews | 138 (11.74%) | 6.00% |
| Case Studies | 92 (7.83%) | 4.05% |
| Observational | 10 (0.85%) | 0.25% |
| Other | 446 (37.96%) | 84.16% |